Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG

Objectives Myasthenia gravis (MG) is a rare, chronic, autoimmune neuromuscular disease which can affect functional and mental aspects of health and health-related quality of life (HRQoL). This study aims to obtain detailed knowledge of the impact of MG on HRQoL in a broad population from the perspective of the patient. Design Prospective, observational, digital, longitudinal real-world study. Setting Adult patients with MG from seven countries (USA, Japan, Germany, UK, Italy, Spain and Canada) downloaded a mobile application onto their phones and entered data about themselves and their MG. Outcome measures Data was collected using the following general and disease-specific patient-reported outcome measurements: EuroQol 5 Domains Health-Related Quality of Life Questionnaire (EQ-5D-5L), Myasthenia Gravis Activities of Daily Living (MG-ADL), Myasthenia Gravis Quality of Life 15-item revised scale (MG-QoL-15r), Hospital Anxiety and Depression Scale (HADS) and Health Utilities Index III (HUI3). Patients were categorised by their self-assessed Myasthenia Gravis Foundation of America (MGFA) class (I–V). Results Baseline results of 841 participants (mean age 47 years, 70% women) are reported . The distribution across the MGFA classes was: 13.9%, 31.0%, 38.1%, 15.5% and 1.6% for classes I–V. The MGFA class was a strong predictor of all aspects of HRQoL, measured with disease-specific and with generic instruments. The domains in which patients with MG most frequently mentioned problems were usual activities, anxiety and depression, tiredness, breathing and vision. The mean total MG-ADL Score was positively associated with increasing MGFA classes: 2.7, 4.4, 6.3 and 8.4 for MGFA classes I–IV. Mean baseline EQ-5D-5L utility was also associated with MGFA classes and was 0.817, 0.766, 0.648 and 0.530 for MGFA class I–IV. Conclusions MG has a large impact on key aspects of health and HRQoL. The impact of this disease increases substantially with increasing disease severity.

[1]  Jonas Jacobi,et al.  Burden of disease in myasthenia gravis: taking the patient’s perspective , 2021, Journal of Neurology.

[2]  R. Mantegazza,et al.  Estimation of myasthenia gravis prevalence in Italy using real-world data , 2021, Journal of the Neurological Sciences.

[3]  S. Dewilde,et al.  Patient-reported impact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG) , 2021, BMJ Open.

[4]  B. Soliven,et al.  Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations , 2021, Journal of clinical medicine.

[5]  M. Leone,et al.  The epidemiology of myasthenia gravis , 2021, Journal of medicine and life.

[6]  H. Andersen,et al.  Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis , 2020, Frontiers in Neurology.

[7]  M. Lipowska,et al.  Determinants of Quality of Life in Myasthenia Gravis Patients , 2020, Frontiers in Neurology.

[8]  G. Cutter,et al.  Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States , 2020, Journal of clinical neuromuscular disease.

[9]  B. K. Vitturi,et al.  Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis , 2020, Neurological Sciences.

[10]  B. Roy,et al.  Exploring outcomes and characteristics of myasthenia gravis: Rationale, aims and design of registry – The EXPLORE-MG registry , 2020, Journal of the Neurological Sciences.

[11]  G. Bonsel,et al.  Does the EQ-5D-5L benefit from extension with a cognitive domain: Testing a multi-criteria psychometric strategy in trauma patients , 2020, Quality of Life Research.

[12]  L. Prieto-Pinto,et al.  Quality of life in refractory generalized myasthenia gravis: A rapid review of the literature. , 2019, Intractable & rare diseases research.

[13]  G. Cutter,et al.  Cross‐sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment , 2019, Muscle & nerve.

[14]  J. Brazier,et al.  Selecting Bolt-On Dimensions for the EQ-5D: Examining Their Contribution to Health-Related Quality of Life. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  M. Hoogendoorn,et al.  Exploring the Impact of Adding a Respiratory Dimension to the EQ-5D-5L , 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

[16]  M. Jo,et al.  Exploratory Study of Dimensions of Health-related Quality of Life in the General Population of South Korea , 2017, Journal of preventive medicine and public health = Yebang Uihakhoe chi.

[17]  John Brazier,et al.  The Use of Health State Utility Values in Decision Models , 2017, PharmacoEconomics.

[18]  M. Conaway,et al.  International clinimetric evaluation of the MG‐QOL15, resulting in slight revision and subsequent validation of the MG‐QOL15r , 2016, Muscle & nerve.

[19]  U. Grittner,et al.  Fatigue in myasthenia gravis: risk factors and impact on quality of life , 2016, Brain and behavior.

[20]  J. Verschuuren,et al.  An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts , 2015, Health and Quality of Life Outcomes.

[21]  Katie Brittain,et al.  The effectiveness of collaborative care for people with memory problems in primary care: results of the CAREDEM case management modelling and feasibility study. , 2014, Health technology assessment.

[22]  A. F. Stern The hospital anxiety and depression scale. , 2014, Occupational medicine.

[23]  J. Brazier,et al.  Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. , 2014, Health technology assessment.

[24]  K. Boye,et al.  Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[25]  T. Kohlmann,et al.  Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  M. Conaway,et al.  MG‐ADL: Still a relevant outcome measure , 2011, Muscle & nerve.

[27]  G. Bonsel,et al.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.

[28]  J. Kugler,et al.  Quality of life and life circumstances in German myasthenia gravis patients , 2010, Health and quality of life outcomes.

[29]  M. Conaway,et al.  Less is more, or almost as much: A 15‐item quality‐of‐life instrument for myasthenia gravis , 2008, Muscle & nerve.

[30]  Monica Milani,et al.  Myasthenia gravis: past, present, and future. , 2006, The Journal of clinical investigation.

[31]  T. T. Haug,et al.  The validity of the Hospital Anxiety and Depression Scale. An updated literature review. , 2002, Journal of psychosomatic research.

[32]  P. Tonali,et al.  Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements , 2001, Neurological Sciences.

[33]  D B Sanders,et al.  Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. , 2000, Neurology.

[34]  G. Wolfe,et al.  Myasthenia gravis activities of daily living profile , 1999, Neurology.

[35]  L. Phillips The Epidemiology of Myasthenia Gravis , 2003, Neurologic clinics.

[36]  R. Snaith,et al.  The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.